134

Why Pfizer stock may not be a worthy investment in the midst of Delta variant concerns

Why Pfizer stock may not be a worthy investment in the midst of Delta variant concerns
Jordan
Major
3 months ago
3 mins read

Almost half of the adults affected in an outbreak of the Delta strain in Israel were fully vaccinated with the Pfizer-BioNTech vaccine, forcing the Israeli authorities to reinstate an indoor mask requirement and other precautions, based on the findings of a report by the Wall Street Journal.

According to Ran Balicer, who chairs the government’s expert advisory council on Covid-19, preliminary results by Israeli health experts indicate that the Delta version was likely responsible for 90% of new infections. 

Pfizer’s stock potentially, as a result, has recently fallen below the 50-day simple moving average (SMA), which is frequently displayed on charts and extensively utilized by traders and market watchers since historical price movement research show it to be an effective trend predictor. Hence, if the selling pressure dominance persists, the PFE stock might see more downside.

PFE stock performance. Source: Finviz.com data

On the other hand, the Wall Street analysts project that the Pfizer-BioNTech vaccine will improve sales, although the evidence suggests that this isn’t the case. Based on 12 analysts’ recommendations for Pfizer stock in the last three months, two suggest to buy, nine recommend hold, and one opts to sell.

Furthermore, Pfizer’s 12-month price projections from the same 12 Wall Street analysts in the last three months reveal the average price prediction is $44.20, with a predicted high of $55.00 and a low of $39.00. This is a 13.39 percent increase over the previous price of $38.98.

Analyst Price Target on PFE. Source: TipRanks.com

The view from Israel

Alon Rappaport, Pfizer’s medical director in Israel, when speaking with local broadcaster Army Radio, believes the Pfizer-BioNTech vaccine is very efficient against the Delta form of COVID-19. The official confirmed:

“The data we have today, accumulating from research we are conducting at the lab and including data from those places where the Indian variant, Delta, has replaced the British variant as the common variant, point to our vaccine being very effective, around 90%, in preventing the coronavirus disease, COVID-19.” 

In addition, antibodies generated by the vaccination were still able to neutralize all tested versions, including Delta, according to a study published this month in Nature magazine by researchers from the University of Texas, Pfizer, and BioNtech.

Uncertainty still looms

Despite the view of the vaccine being effective, the World Health Organization encouraged fully vaccinated individuals to continue to wear masks, maintain social distance, and adopt other Covid-19 pandemic safety precautions on Friday.

With recent measures taken by the government in Israel, it appears the jury is still out on the Pfizer vaccine and its stock as the highly infectious Delta variant quickly spreads throughout the world. 

Track the latest Pfizer (PFE) stock price here, use our full-featured chart to forecast your next move, and read the latest news.

What we like:

Commission-free investing

Trade in real time

No account minimum

Simple interface

Cryptocurrency trading

Rating

Visit Now

Join us on Twitter or Telegram

Or follow us on Flipboard Flipboard

Like the article? Vote up or share on your social media

Recommended content

Weekly Finance Digest

By subscribing you agree with Finbold T&C’s

Jordan Major
Author

Jordan is an investor and market analyst. He's passionate about stocks, ETFs, blockchain, and digital assets. At Finbold.com, he delves into the technicalities to obtain future trends for new market traders and gives insights into user-friendly platforms for beginners.